home / stock / aqst / aqst news

AQST News and Press, Aquestive Therapeutics Inc. From 04/25/24

Stock Information
Company Name: Aquestive Therapeutics Inc.
Stock Symbol: AQST
Market: NASDAQ
Website: aquestive.com
Menu
AQST AQST Quote AQST Short AQST News AQST Articles AQST Message Board
Get AQST Alerts

News, Short Squeeze, Breakout and More Instantly...
AQST - Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET

WARREN, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolo...
AQST - OPI, RVNC and AQST are among after hour movers

2024-04-22 16:53:54 ET Gainers: Oportun Financial  ( OPRT ) +5% . Humacyte ( HUMA ) +2% . Revance Therapeutics ( RVNC ) +2% . Office Properties Income  ( OPI ) +2% . Axcelis Technologies ( ACLS ) +1% . Losers: C...

AQST - Coming FDA Approvals Could Send These 3 Drug Stocks Soaring

2024-04-17 08:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In the biotech and pharmaceutical world, FDA approval is the number one needle mover for drug stocks. Why? Because FDA approval for a drug or treatment can bring years or even decades of steady...

AQST - Aquestive Therapeutics to Present Crossover Study Data for Libervant(TM) (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology

WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolo...
AQST - Aquestive Therapeutics a new overweight at Piper on oral film products

2024-04-11 14:48:40 ET More on Aquestive Therapeutics Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024 Aquestive Therapeutics, Inc. (AQST) Q4 2023 Earnings Call Transcript Aquestive Therapeutics, Inc. 2023 Q4 - Results - Earnings ...

AQST - Piper starts Aquestive at overweight, cites allergy reaction treatment

2024-04-11 12:38:15 ET More on Aquestive Therapeutics Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024 Aquestive Therapeutics, Inc. (AQST) Q4 2023 Earnings Call Transcript Aquestive Therapeutics, Inc. 2023 Q4 - Results - Earnings ...

AQST - Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024

2024-04-09 01:25:13 ET Summary Aquestive Therapeutics has achieved positive Phase III data for their Anaphylm epinephrine sublingual film, showing comparable efficacy to auto-injectors. The company is moving forward with plans to file a New Drug Application (NDA) and has several u...
AQST - Aquestive Therapeutics files for $250M mixed securities shelf

2024-04-03 17:38:46 ET More on Aquestive Therapeutics Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1 Aquestive Therapeutics slumps 13%, prices $75M offering Aquestive Therapeutics reports mixed Q4 results; initiates FY24 outlook ...

AQST - Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolo...

AQST - Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock

WARREN, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery t...
Previous 10 Next 10